Evidence Level
Emerging
Pterostilbene is increasingly viewed as a practical upgrade over resveratrol due to its dramatically superior pharmacokinetics. Kapetanovic et al. (2011) established the favorable bioavailability profile. Riche et al. (2014) published the most significant human trial, demonstrating blood pressure reduction and cardiovascular benefits. Chang et al. (2012) showed cognitive benefits in aging animal models. McCormack and McFadden (2013) provided a comprehensive review of pterostilbene's anticancer, anti-inflammatory, and metabolic properties. The main concern from the Riche trial was a dose-dependent increase in LDL cholesterol at the highest dose (250mg 2x daily), which warrants monitoring.